Celularity Inc (CELU) Stock Price, Quote & News

Company Profile

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 768 2170

Website: www.celularity.com

Address:

170 Park Avenue, Florham Park, United States

ToxicAvenger Jul. 15 at 12:33 PM

$CELU saw they were going to start stem cell treatments in Florida under new laws.

0 · Reply

KingStocks1 Jul. 15 at 12:31 PM

$CELU going under $2. What a joke

0 · Reply

Andy_mc Jul. 15 at 12:29 PM

$CELU Holding for a swing. Recommend those who join do the same. We're waiting for the real move off earnings. Keep in mind that spike to $7 in PM was only there for like 2-3 mins, best ignored. Must just be due to liquidity out of hours.

0 · Reply

Nmiller33 Jul. 15 at 12:19 PM

$CELU why did this touch so high pre market

0 · Reply

elitechrisvp Jul. 15 at 12:13 PM

$CELU 🤣

0 · Reply

TruthTooPower Jul. 15 at 12:10 PM

$CELU !!! WTF???? Shorts Need Dealt With!!!

0 · Reply

JL416 Jul. 15 at 11:56 AM

$BLMZ $CELU $GRO $IBG $XAGE told ya🚀🚀🚀

0 · Reply

stockWare Jul. 15 at 11:36 AM

$CELU this went to 7.85 early this morning, has related news catalyst $IBG $XAGE $MSPR $GRO

1 · Reply

Bbboston Jul. 15 at 11:35 AM

$CELU So typical. Up $1.70 now looks like it is going to finish the day in red!!!

0 · Reply

themacromindset Jul. 15 at 11:34 AM

$CELU volume increase Quick Scalp/Buy Alert 2.39

0 · Reply

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Jul 1, 2025, 8:30 AM EDT - 14 days ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jun 10, 2025, 4:15 PM EDT - 4 weeks ago

Celularity Announces Chief Financial Officer Transition

Jun 2, 2025, 8:00 AM EDT - 6 weeks ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

May 30, 2025, 5:30 PM EDT - 6 weeks ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

May 9, 2025, 9:15 AM EDT - 2 months ago

Celularity Announces Full Year 2024 Operating and Financial Results

Apr 25, 2025, 5:30 PM EDT - 2 months ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 14, 2025, 8:00 AM EDT - 3 months ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Feb 25, 2025, 8:00 AM EST - 4 months ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 24, 2025, 8:00 AM EST - 5 months ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Dec 10, 2024, 8:00 AM EST - 7 months ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 6, 2024, 8:00 AM EST - 7 months ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Nov 27, 2024, 5:00 PM EST - 8 months ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 20, 2024, 8:30 AM EST - 8 months ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Oct 23, 2024, 8:30 AM EDT - 9 months ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 18, 2024, 6:00 PM EDT - 9 months ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 16, 2024, 5:15 PM EDT - 9 months ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Sep 5, 2024, 4:05 PM EDT - 11 months ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 28, 2024, 4:45 PM EDT - 11 months ago

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 23, 2024, 5:00 PM EDT - 11 months ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jun 3, 2024, 8:38 AM EDT - 1 year ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 9:15 AM EDT - 1 year ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 19, 2024, 5:30 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 8, 2024, 9:00 AM EDT - 1 year ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Mar 26, 2024, 9:00 AM EDT - 1 year ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 20, 2024, 9:15 AM EDT - 1 year ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 14, 2024, 9:15 AM EDT - 1 year ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 12, 2024, 9:20 AM EDT - 1 year ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 7, 2024, 9:35 AM EST - 1 year ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Feb 23, 2024, 4:10 PM EST - 1 year ago

Celularity Announces 1-for-10 Reverse Stock Split

Feb 14, 2024, 4:05 PM EST - 1 year ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 1, 2024, 9:00 AM EST - 1 year ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Jan 25, 2024, 9:00 AM EST - 1 year ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 18, 2024, 1:40 PM EST - 1 year ago

Celularity Releases CEO Letter to Shareholders

Jan 4, 2024, 1:00 PM EST - 1 year ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Jan 3, 2024, 12:00 PM EST - 1 year ago

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Oct 18, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Sep 7, 2023, 4:10 PM EDT - 2 years ago

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Jul 27, 2023, 9:07 AM EDT - 2 years ago

Celularity Inc. Announces $3 Million Registered Direct Offering

Jul 27, 2023, 9:00 AM EDT - 2 years ago

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Jul 18, 2023, 9:00 AM EDT - 2 years ago

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Jun 29, 2023, 4:05 PM EDT - 2 years ago

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Jun 1, 2023, 9:15 AM EDT - 2 years ago

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

May 23, 2023, 10:56 AM EDT - 2 years ago

CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS

ToxicAvenger Jul. 15 at 12:33 PM

$CELU saw they were going to start stem cell treatments in Florida under new laws.

0 · Reply

KingStocks1 Jul. 15 at 12:31 PM

$CELU going under $2. What a joke

0 · Reply

Andy_mc Jul. 15 at 12:29 PM

0 · Reply

Nmiller33 Jul. 15 at 12:19 PM

$CELU why did this touch so high pre market

0 · Reply

elitechrisvp Jul. 15 at 12:13 PM

$CELU 🤣

0 · Reply

TruthTooPower Jul. 15 at 12:10 PM

$CELU !!! WTF???? Shorts Need Dealt With!!!

0 · Reply

JL416 Jul. 15 at 11:56 AM

$BLMZ $CELU $GRO $IBG $XAGE told ya🚀🚀🚀

0 · Reply

stockWare Jul. 15 at 11:36 AM

$CELU this went to 7.85 early this morning, has related news catalyst $IBG $XAGE $MSPR $GRO

1 · Reply

Bbboston Jul. 15 at 11:35 AM

$CELU So typical. Up $1.70 now looks like it is going to finish the day in red!!!

0 · Reply

themacromindset Jul. 15 at 11:34 AM

$CELU volume increase Quick Scalp/Buy Alert 2.39

0 · Reply

JohnnySwag Jul. 15 at 11:30 AM

$CELU Building a small position here. First target is VWAP. Volume profile says potential to $3.70. Not betting the bank - that's for sure.

0 · Reply

JackSch Jul. 15 at 11:15 AM

$CELU is it true their cash burn is over 15MM QUARTER but they have less than 1MM in cash? That seems messed up!

1 · Reply

SupremeTrader93 Jul. 15 at 11:12 AM

$HCTI .02 support holding well 👍👍… $BLMZ $CELU $CYCC $WINT moving nice in pre market . Looking forward for today 👏 stick to your plans , trade well , no chasing ! Stay disciplined let’s goooo my fellow traders 🤓

0 · Reply

moneymarker20188 Jul. 15 at 11:07 AM

$CELU in this will go $3S

1 · Reply

singa_stock Jul. 15 at 11:06 AM

$CELU If you are shorting here at 2.6, you’ve already missed the boat. If you are not buying, let me point out that it hit almost $8 this morning.

0 · Reply

luckydog2 Jul. 15 at 11:00 AM

$CELU Low Float, High Short Interest, Undervalued Stock Price....It's about time.

0 · Reply

Mohamed209 Jul. 15 at 10:56 AM

$CELU i have feeling this one will pump again

0 · Reply

JL416 Jul. 15 at 10:53 AM

$XAGE looks rippy $BLMZ $CELU $IBG $GRO

0 · Reply

singa_stock Jul. 15 at 10:42 AM

$CELU Today is a pump and dump for sure. However, company will release earnings soon. About $75M-$100M revenue expected. Do your DD. Today is just a preview of what can happen. It All time high in AM. With any good news between today and end of July, $20 expected.

1 · Reply

joedoe007 Jul. 15 at 10:41 AM

$CELU This CELu stonk seems like a $RYET or $CYCU type pump n dump scam or fraud mover , no??

1 · Reply

luckydog2 Jul. 15 at 10:40 AM

$CELU What ever happened to this guy???

1 · Reply

Mohamed209 Jul. 15 at 10:38 AM

$CELU i just found this news it’s 5 days ago but it’s really good . https://finance.yahoo.com/news/celularity-fountain-life-announce-partnership-123000991.html

0 · Reply

Market Cap	50.53M
Revenue (ttm)	54.22M
Net Income (ttm)	-57.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.77%
Debt to Equity Ratio	4.78

Volume	99,900
Avg Vol	80,568
Day's Range	N/A - N/A
Shares Out	23.95M
Stochastic %K	95%
Beta	0.74
Analysts	Strong Buy
Price Target	$16.00